A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Francesco Forconi
Advertisement
Articles by Francesco Forconi
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
3
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
4
Urologic Oncologist Answers Top Searched Questions in Bladder Cancer
5